Oscar Health Inc. (OSCR) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
75 VARICK STREET NEW YORK, NY 10013 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 6324 - Hospital and Medical Service Plans (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in millions)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 2,560 | 2,956 | 1,691 | |||
| Cash and cash equivalents | 1,870 | 1,559 | 1,104 | |||
| Short-term investments | 690 | 1,397 | 587 | |||
| Other current assets | 7 | 6 | ||||
| Other undisclosed current assets | 494 | 1,159 | 615 | |||
| Total current assets: | 3,061 | 4,122 | 2,306 | |||
| Noncurrent Assets | ||||||
| Property, plant and equipment | 62 | 60 | 47 | |||
| Long-term investments and receivables | 365 | 223 | 844 | |||
| Long-term investments | 365 | 223 | 844 | |||
| Restricted cash and investments | 30 | 27 | 28 | |||
| Deferred income tax assets | 1 | |||||
| Other noncurrent assets | 83 | 95 | 96 | |||
| Total noncurrent assets: | 540 | 405 | 1,016 | |||
| TOTAL ASSETS: | 3,601 | 4,527 | 3,322 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 273 | 298 | 235 | |||
| Other undisclosed accounts payable and accrued liabilities | 273 | 298 | 235 | |||
| Other undisclosed current liabilities | 2,156 | 2,966 | 1,618 | |||
| Total current liabilities: | 2,429 | 3,264 | 1,852 | |||
| Noncurrent Liabilities | ||||||
| Long-term debt and lease obligation | 299 | 298 | ||||
| Long-term debt, excluding current maturities | 299 | 298 | ||||
| Liabilities, other than long-term debt | 68 | 72 | 77 | |||
| Other liabilities | 68 | 72 | 77 | |||
| Total noncurrent liabilities: | 366 | 370 | 77 | |||
| Total liabilities: | 2,795 | 3,634 | 1,929 | |||
| Equity | ||||||
| Equity, attributable to parent, including: | 804 | 890 | 1,387 | |||
| Treasury stock, value | (3) | (3) | (3) | |||
| Additional paid in capital | 3,682 | 3,509 | 3,394 | |||
| Accumulated other comprehensive income (loss) | 1 | (10) | (4) | |||
| Accumulated deficit | (2,877) | (2,606) | (2,000) | |||
| Other undisclosed equity, attributable to parent | 0 | 0 | 0 | |||
| Equity, attributable to noncontrolling interest | 2 | 2 | 5 | |||
| Total equity: | 806 | 892 | 1,393 | |||
| TOTAL LIABILITIES AND EQUITY: | 3,601 | 4,527 | 3,322 | |||
Income Statement (P&L) ($ in millions)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Revenues | 5,863 | 3,964 | 1,839 | ||
| Premiums earned, net | 5,686 | 3,871 | 1,831 | ||
| Cost of revenue | (4,644) | (3,256) | (1,569) | ||
| Policyholder benefits and claims incurred, net | (4,642) | (3,281) | (1,624) | ||
| Gross profit: | 1,219 | 708 | 270 | ||
| Operating expenses | (340) | (310) | (265) | ||
| Other undisclosed operating loss | (1,115) | (988) | (549) | ||
| Operating income (loss): | (236) | (590) | (544) | ||
| Nonoperating income (expense) | (7) | (1) | |||
| Investment income, nonoperating | (1) | ||||
| Other nonoperating expense | (1) | ||||
| Interest and debt expense | (25) | (23) | (25) | ||
| Income (loss) from continuing operations before equity method investments, income taxes: | (267) | (612) | (571) | ||
| Other undisclosed income from continuing operations before income taxes | 2 | ||||
| Income (loss) from continuing operations before income taxes: | (267) | (610) | (571) | ||
| Income tax expense (benefit) | (3) | 1 | (1) | ||
| Income (loss) from continuing operations: | (271) | (610) | (571) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (571) | |
| Net income (loss): | (271) | (610) | (571) | ||
| Net income (loss) attributable to noncontrolling interest | (0) | 3 | (1) | ||
| Net income (loss) available to common stockholders, basic: | (271) | (606) | (573) | ||
| Dilutive securities, effect on basic earnings per share | |||||
| Net income (loss) available to common stockholders, diluted: | (271) | (606) | (573) | ||
Comprehensive Income ($ in millions)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | ||
|---|---|---|---|---|---|
| Net income (loss): | (271) | (610) | (571) | ||
| Other undisclosed comprehensive income (loss) | 11 | (6) | (5) | ||
| Comprehensive income (loss): | (260) | (616) | (576) | ||
| Comprehensive income (loss), net of tax, attributable to noncontrolling interest | (0) | 3 | (1) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (260) | (612) | (577) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.